U.S. markets closed

Akers Biosciences, Inc. (AKER)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.27000.0000 (0.00%)
At close: 4:00PM EDT

2.2500 -0.02 (-0.88%)
After hours: 6:05PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.2700
Open2.3200
Bid2.2600 x 800
Ask2.3400 x 800
Day's Range2.2264 - 2.3250
52 Week Range1.5500 - 10.5600
Volume65,248
Avg. Volume1,131,760
Market Cap19.804M
Beta (5Y Monthly)0.23
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hedge Funds Are Nibbling On Akers Biosciences Inc (AKER)
    Insider Monkey

    Hedge Funds Are Nibbling On Akers Biosciences Inc (AKER)

    At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

  • TheStreet.com

    Microcap Akers Biosciences Spikes on Covid-Vaccine Progress

    Akers and Premas Biotech are three steps into a four-step plan that could lead to clinical trials of a vaccine candidate.

  • Akers Says It's Halfway Through Plan To Develop COVID-19 Vaccine Candidate
    Benzinga

    Akers Says It's Halfway Through Plan To Develop COVID-19 Vaccine Candidate

    Akers Biosciences Inc (NASDAQ: AKER), which said earlier this week that it is one step closer to identifying a coronavirus vaccine candidate, announced another successful milestone Wednesday in its vaccine development program.The New Jersey-based company said that it, along with developmental partner Premas Biotech, has successfully completed the second milestone of successful expression of the three coronavirus antigens -- spike, envelop and membrane --selected for their vaccine candidate.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter."The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain," according to Akers. Premas will now move ahead with purification and post-expression processing that will lead to a scaling up of the antigen, according to a press release. The company is now halfway through a four-milestone plan that it believes will lead to the commencement of clinical trials, Akers Executive Chairman Christopher Schreiber said in a statement. Akers shares were advancing 6.14% to $6.05 at the time of publication Wednesday. Related Links:Analyst Projects Over 130% Upside In This Biopharma Teva Analyst Says Shares Are Pricing In Too Much Risk See more from Benzinga * The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index * The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.